When exploring advanced biochemical research, one frequently encounters the term pt 161 peptide, often conflated with various synthetic compounds in literature. It is essential to clarify ATN 161 (6058) by Tocris, Part of Bio-Techne that in scientific databases, the primary subject of interest is ATN-161, a well-documented five-amino acid peptide that serves as a focal PHSCN peptide (licensed as ATN-161) is an effective α5β1 integrin inhibitor that has advanced to phase II clinical trials to treat solid tumors. point for researchers studying cell signaling and receptor dynamics.
The Biochemical Profile of ATN-161
ATN-161 is a non-RGD based integrin binding peptide derived from the synergy region of fibronectin. Its chemical structure, often noted as Ac-PHSCN-NH2, makes it a specialized tool for laboratory investigations. Unlike standard RGD motifs, this small peptide antagonist of integrin alpha5beta1 interacts specifically with the N-terminus of the beta-1 region, which is a critical area of focus for those analyzing angiogenesis and cellular migration.
As someone who tracks peptide research, I find the specificity of the PHSCN peptide (licensed as ATN-161) to be particularly fascinating. It acts as an alpha v beta 1 inhibi by ME Cianfrocca · 2006 · Cited by 225 — Abstract: To evaluate the toxicity, pharmacological and biological properties of ATN-161, a five -amino-acid peptide derived from the synergy region of tor and is recognized as a novel Tactic Pharma was developing a five amino acid peptide, ATN 161, for the treatment of cancer. ATN 161 is a non-competitive inhibitor of the fibronectin synergy. integrin alpha5beta1 antagonist. Because it selectively binds to and blocks the receptor for integrin, it has been a frequent subject in studies regarding the inhibition of tumor growth, angiogenesis, and metastasis.
E-E-A-T and Research Integrity
When reviewing data on The Integrin Binding Peptide, ATN-161, it is vital to rely on peer-reviewed literature and high-quality chemical suppliers. M Bcl-2-like protein 11 142-161, MRPEIWIAQELRRIGDEFNA any of the studies cited in academic repositories, such as PubMed, underscore the importance of purity and structural integrity in these compounds. Whether you are looking at the Bcl-2-like protein 11 142-161 or the SHBG141–161 peptide, the nomenclature can be confusing. However, ATN 161 is a α5β1 integrin receptor antagonist that remains distinct from other epitope markers.
Key Technical Specifications
* Molecular Composition: Five-amino acid sequence (Ac-PHSCN-NH2).
* Primary Function: Integrin receptor antagonism (specifically α5β1 and αvβ3).
* Research Application: Investigated for antiangiogenic properties and cell adhesion inhibition.
* Synthe ATN-161: Uses, Interactions, Mechanism of Action sis: Often produced via squaric acid-mediated synthesis in ATN-161 peptide functionalized reversibly crosslinked materials.
Observations on Experimental Use
In my experience analyzing laboratory reports, the distinction between ATN-161 and other compounds with "161" in their name—such as Tb-161 (a radionuclide) or MAGE-1 Antigen (161-169)—is paramount. A Phase 1 Trial of the Antiangiogenic Peptid ATN-161 | Integrin antagonist | CAS 262438-43-7 e ATN-161 highlighted its potential in modulating biological pathways, yet it is crucial to remember that these are strictly for controlled research environments.
The Integrin-binding peptide ATN-161 is frequently utilized in murine models to evaluate its capacity to reduce liver metastasis. Its role as a non-competitive inhibitor of the fibronectin synergy site is what sets it apart from traditional antagonists.
Conclusion
Whether you are a student of biochemistry or a researcher focusing on cellular signaling, understanding the nuance of ATN-161 is key. It is not merely a number; it is a meticulously designed five amino acid peptide, ATN 161, that provides significant value in the study of integrin-mediated processes. Always ensure that when sourcing these materials, you prioritize suppliers who provide comprehensive HPLC analysis to confirm the identity and purity of the peptide. By focusing on the verified mechanisms of this small peptide antagonist of integrin alpha5beta1, we can better appreciate the complex nature of protein-protein interactions in experimental settings.